Photo from archive.org
Highlights • NACT use among SGO members for ovarian cancer is explored given recent trials.• Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively.• Laparoscopy use has increased both… Click to show full abstract
Highlights • NACT use among SGO members for ovarian cancer is explored given recent trials.• Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively.• Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer.• Very high optimal cytoreduction rates are reported from SGO members.• Despite recent studies, SGO members don't regularly treat patients with NACT/ID.
Keywords:
chemotherapy management;
sgo members;
ovarian cancer;
neoadjuvant chemotherapy;
role neoadjuvant;
cancer
Journal Title: Gynecologic Oncology Reports
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Gynecologic Oncology Reports
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!